BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Integrated Genomics, Inc. Licenses ERGO To Danish Natural Ingredients Company Chr. Hansen


10/19/2005 5:12:21 PM

CHICAGO, Dec. 2 /PRNewswire/ -- Integrated Genomics Inc., a leading provider of bioinformatics tools to the food industry, has licensed its proprietary ERGO database and genomic discovery system to Chr. Hansen, a Danish natural ingredients company. Optimized for analysis of microorganisms, ERGO integrates biological data from genomics, biochemistry, gene expression studies, genetics and literature.

Reaching beyond conventional systems for functional analysis of DNA sequences, Integrated Genomics' platform combines pattern-based analysis with comparative genomics and enables visualization of genes in the contexts of regulation, gene expression data, phylogeny, chromosomal neighborhoods and identification of natural gene fusions. ERGO contains more than 700 genomes at various stages of completion, as well as the largest available collection of networked cellular pathways. Under the terms of the agreement, Chr. Hansen scientists will use the ERGO system to study naturally occurring microorganisms that live in the human gut. Integrated Genomics has sequenced and fully annotated a number of beneficial probiotic bacteria.

"We have found the ERGO discovery system an exceptionally useful tool for studying probiotics, and expect that it will assist us in developing new ingredients that will prove beneficial to human nutrition," said Dr. Eric Johansen, head of the Applied Biotechnology Division at Chr. Hansen. "ERGO provides us with a depth of data and insight into metabolic processes that we could not have found elsewhere," added Dr. Martin Pedersen of Chr. Hansen's Department of Genomics and Strain Development.

"Integrated Genomics is pleased to work with scientists at Chr. Hansen in this important nutritional study," said Roelf Datema, CEO of Integrated Genomics. "We are confident that the ERGO platform can contribute to the understanding of probiotic bacteria and human nutrition."

Chr. Hansen and Integrated Genomics expect the current project to run through 2005.

About Integrated Genomics

Integrated Genomics ( http://www.integratedgenomics.com/ ) is a provider of bioinformatics products and services for the life science industry, with a recent focus on the use of in silico strategies for metabolic engineering of microbes in the chemical, food, and agricultural industries. The company's expertise in microbial genomics includes genome sequencing, genome analysis and custom bioinformatics. In recent years IG has developed and distributed ERGO, the most advanced and comprehensive bioinformatics suite for microbial genomics on the market. ERGO contains the largest available integration of microbial genome data, including genome-derived metabolic reconstructions and representing the chemical reaction networks of metabolic pathways.

About Chr. Hansen

Chr. Hansen ( http://www.chr-hansen.com/ ) develops natural ingredient solutions for the food, pharmaceutical, nutritional and agricultural industries, in close cooperation with our customers and partners. Our fundamental aim is to improve the quality of food and people's health, using natural ingredients and processes.

Chr. Hansen spends 7% of revenues on R&D with a strong focus on genomics, in order to better understand our products and processes as well as the behavior of our cultures in our customers' food products. Chr. Hansen believes that a better knowledge of genes in food microorganisms is needed in order to produce ingredients, which can help overcome some of the current lifestyle associated diseases. Moreover, it is important for documenting specific health claims associated with particular probiotic strains. Ultimately, genomics may allow determination of the mode of action of specific beneficial effects.

Integrated Genomics Inc.

CONTACT: Kathe Andrews-Cramer, PhD, Director of Business Development ofIntegrated Genomics, +1-312-491-0846, ext. 371,kcramer@integratedgenomics.com , or Eric Johansen, PhD, Vice President,Applied Biotechnology of Chr. Hansen A/S, Horsholm, Denmark,+(45) 45 74 84 64, eric.johansen@dk.chr-hansen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES